Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Marie

Showing results (131-140 of 184) with videos related to

Pageof 19
Sort By:
Current Opinion in Nephrology and Hypertension|July 1, 1994
Adynamic bone disease in patients with uremiaA Fournier, P H Yverneau, P Hué, et al.
Academic Medicine : Journal of the Association of American Medical Colleges|September 30, 2008
Speaking the right language: the scientific method as a framework for a continuous quality improvement program within academic medical research compliance unitsKurt B Nolte, Douglas M Stewart, Kevin C O'Hair, et al.
Journal for Immunotherapy of Cancer|July 7, 2019
Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibitionAbdul Rafeh Naqash, Ebenezer Appah, Li V Yang, et al.
Nephron|January 1, 1986
Comparative evaluation of bone aluminum content and bone histology in patients on chronic hemodialysis and hemofiltrationJ L Sebert, A Fournier, P Leflon, et al.
BMJ Open|February 16, 2024
Can RESPiratory hospital Admissions in children with cerebral palsy be reduced? A feasibility randomised Controlled Trial pilot study protocol (RESP-ACT)Rachael Marpole, A Marie Blackmore, Andrew C Wilson, et al.
Neurobiology of Disease|July 25, 2006
The dynamism of PABPN1 nuclear inclusions during the cell cycleA Marie-Josée Sasseville, Antoine W Caron, Lucie Bourget, et al.
Nephron|January 1, 1989
Disappearance of aluminic bone disease in a long term asymptomatic dialysis population restricting A1(OH)3 intake: emergence of an idiopathic adynamic bone disease not related to aluminumP Morinière, M Cohen-Solal, S Belbrik, et al.
Clinical Therapeutics|October 9, 2007
Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjectsA Marie O'Farrell, Andre van Vliet, Khalid Abou Farha, et al.
Experimental Neurology|June 9, 2009
Excitotoxic-mediated transcriptional decreases in HCN2 channel function increase network excitability in CA1Brendan E L Adams, Christopher A Reid, Damian Myers, et al.
Nature Communications|November 19, 2017
Uplift of the central transantarctic mountainsPhil Wannamaker, Graham Hill, John Stodt, et al.
Pageof 19

Showing results (131-140 of 184) with videos related to

Sort By:
Pageof 19
Current Opinion in Nephrology and Hypertension|July 1, 1994
Adynamic bone disease in patients with uremiaA Fournier, P H Yverneau, P Hué, et al.
Academic Medicine : Journal of the Association of American Medical Colleges|September 30, 2008
Speaking the right language: the scientific method as a framework for a continuous quality improvement program within academic medical research compliance unitsKurt B Nolte, Douglas M Stewart, Kevin C O'Hair, et al.
Journal for Immunotherapy of Cancer|July 7, 2019
Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibitionAbdul Rafeh Naqash, Ebenezer Appah, Li V Yang, et al.
Nephron|January 1, 1986
Comparative evaluation of bone aluminum content and bone histology in patients on chronic hemodialysis and hemofiltrationJ L Sebert, A Fournier, P Leflon, et al.
BMJ Open|February 16, 2024
Can RESPiratory hospital Admissions in children with cerebral palsy be reduced? A feasibility randomised Controlled Trial pilot study protocol (RESP-ACT)Rachael Marpole, A Marie Blackmore, Andrew C Wilson, et al.
Neurobiology of Disease|July 25, 2006
The dynamism of PABPN1 nuclear inclusions during the cell cycleA Marie-Josée Sasseville, Antoine W Caron, Lucie Bourget, et al.
Nephron|January 1, 1989
Disappearance of aluminic bone disease in a long term asymptomatic dialysis population restricting A1(OH)3 intake: emergence of an idiopathic adynamic bone disease not related to aluminumP Morinière, M Cohen-Solal, S Belbrik, et al.
Clinical Therapeutics|October 9, 2007
Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjectsA Marie O'Farrell, Andre van Vliet, Khalid Abou Farha, et al.
Experimental Neurology|June 9, 2009
Excitotoxic-mediated transcriptional decreases in HCN2 channel function increase network excitability in CA1Brendan E L Adams, Christopher A Reid, Damian Myers, et al.
Nature Communications|November 19, 2017
Uplift of the central transantarctic mountainsPhil Wannamaker, Graham Hill, John Stodt, et al.
Pageof 19